We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In anticipation of proposed guidance on biosimilar interchangeability, AbbVie is requesting that the FDA hold a hearing to ensure the agency considers all viewpoints. Read More
The FDA is postponing its decision on BioMarin’s investigational drug drisapersen for Duchenne muscular dystrophy, saying the review is still under way. Read More